Aware Super Pty Ltd as trustee of Aware Super Acquires New Holdings in Neurocrine Biosciences, Inc. $NBIX

Aware Super Pty Ltd as trustee of Aware Super acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 136,786 shares of the company’s stock, valued at approximately $18,020,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NBIX. State of Michigan Retirement System lifted its stake in shares of Neurocrine Biosciences by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 24,181 shares of the company’s stock worth $3,186,000 after acquiring an additional 600 shares during the period. Principal Financial Group Inc. raised its holdings in Neurocrine Biosciences by 5.2% during the first quarter. Principal Financial Group Inc. now owns 238,161 shares of the company’s stock worth $31,375,000 after purchasing an additional 11,784 shares in the last quarter. Chicago Partners Investment Group LLC raised its holdings in Neurocrine Biosciences by 37.9% during the first quarter. Chicago Partners Investment Group LLC now owns 7,389 shares of the company’s stock worth $969,000 after purchasing an additional 2,030 shares in the last quarter. Diversify Wealth Management LLC acquired a new stake in Neurocrine Biosciences in the first quarter worth approximately $210,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Neurocrine Biosciences by 0.8% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,146 shares of the company’s stock worth $3,313,000 after purchasing an additional 195 shares during the period. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Julie Cooke sold 36,937 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $156.22, for a total value of $5,770,298.14. Following the transaction, the insider owned 22,374 shares of the company’s stock, valued at approximately $3,495,266.28. This trade represents a 62.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ingrid Delaet sold 4,367 shares of the business’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $181.02, for a total value of $790,514.34. Following the sale, the insider owned 16,225 shares in the company, valued at approximately $2,937,049.50. The trade was a 21.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 394,172 shares of company stock valued at $62,221,181 over the last 90 days. 4.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Canaccord Genuity Group increased their price target on Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, April 7th. BMO Capital Markets boosted their price objective on Neurocrine Biosciences from $144.00 to $170.00 and gave the stock a “market perform” rating in a research note on Monday. Weiss Ratings lowered Neurocrine Biosciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, July 10th. Sanford C. Bernstein initiated coverage on Neurocrine Biosciences in a research note on Friday, May 22nd. They set an “outperform” rating and a $221.00 target price for the company. Finally, Citigroup lifted their target price on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $191.67.

Neurocrine Biosciences Stock Down 0.3%

NBIX opened at $171.55 on Friday. The firm has a market cap of $17.25 billion, a PE ratio of 26.43, a P/E/G ratio of 0.65 and a beta of 0.39. The business has a fifty day simple moving average of $163.37 and a 200-day simple moving average of $143.60. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $181.18.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.